NCT01629758View on ClinicalTrials.gov

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Neoplasms by Site
Interventions
BIOLOGICAL

Denenicokin

BIOLOGICAL

Nivolumab

Trial Locations (5)

21231

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore

33612

Moffitt Cancer Center, Tampa

85258

Oncology Research Associates, Pllc D/B/A, Scottsdale

98109

Seattle Cancer Care Alliance, Seattle

06520

Yale University School Of Medicine, New Haven

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01629758 - Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | Biotech Hunter | Biotech Hunter